Hiroshi Matsui

This inventor holds 14 USPTO granted patents, primarily in Medicinal Chemistry. Top assignees: Kyoto Pharmaceutical Industries, Ltd., Sankyo Company, Limited. Active years: 1990-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroshi Matsui. Retrieved from https://idiyas.com/inventor/hiroshi-matsui-6z82zm8o

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14

% Patents Active = 64.3

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 61(Granted Patents)

Company Filing History:

10 out of 26

Kyoto Pharmaceutical Industries, Ltd.

patents

4 out of 613

Sankyo Company, Limited

patents

Years Active: 1990-2009

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Carbapenem Derivatives

Lipid Peroxidation Inhibitors

Indolyl Derivatives

Pharmaceutical Use

Medicinal Use

Intermediate Compounds

Production Method

Pharmaceutical Composition

Inhibitors

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7557123 - Heterocyclic compound and medicinal use thereof (2009-07-07),

2. RE38970 - Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors (2006-02-06),

3. 6872732 - Heterocyclic derivatives and medicinal use thereof (2005-03-29),

4. 6589963 - Heterocyclic compounds and salts thereof and medicinal use of the same (2003-07-08),

5. 6489475 - Method of producing heterocyclic derivatives (2002-12-03),

6. 6414012 - Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof (2002-07-02),

7. 6410525 - Carbapenem derivatives, utilization thereof and intermediate compounds of the same (2002-06-25),

8. 6342494 - Carbapenem compounds, use thereof, and intermediate compounds of the same (2002-01-29),

9. 6200988 - Heterocyclic derivatives and pharmaceutical use thereof (2001-03-13),

10. 6127403 - Method for inhibiting acyl-CoA : cholesterol acyltransferase (2000-10-03),

11. 6063806 - Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or (2000-05-16),

12. 5990150 - Heterocyclic derivatives, method of production thereof and (1999-11-23),

13. 5538973 - Imidazole derivative, pharmaceutical use thereof, and intermediate (1996-07-23),

14. 4937242 - 1,4-dihydropyridine derivatives and pharmaceutical composition thereof (1990-06-26),

Title: Hiroshi Matsui: Innovator in Medicinal Chemistry

Introduction

Hiroshi Matsui is a prominent inventor based in Nara, Japan. He has made significant contributions to the field of medicinal chemistry, holding a total of 14 patents. His work focuses on developing novel compounds with therapeutic applications, particularly in the treatment of diabetes and related conditions.

Latest Patents

Matsui's latest patents include a heterocyclic compound with medicinal uses. This compound is designed to serve as a hypoglycemic agent, an insulin resistance improver, and a therapeutic agent for diabetes and its complications. Another notable patent involves indolyl or indolinyl derivatives that act as ACAT or lipid peroxidation inhibitors. These compounds exhibit superior activity in preventing arteriosclerosis and other cardiovascular diseases.

Career Highlights

Throughout his career, Matsui has worked with notable companies such as Kyoto Pharmaceutical Industries, Ltd. and Sankyo Company, Limited. His innovative research has led to advancements in the pharmaceutical industry, particularly in the development of drugs that target metabolic disorders.

Collaborations

Matsui has collaborated with esteemed colleagues, including Hiroaki Shirahase and Shoji Kamiya. These partnerships have fostered a collaborative environment that enhances the research and development of new medicinal compounds.

Conclusion

Hiroshi Matsui's contributions to medicinal chemistry and his extensive patent portfolio underscore his role as a leading inventor in the field. His innovative work continues to impact the development of therapeutic agents for critical health issues.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]